AcquisitionsApr 16, 2026, 07:12 AM
MeiraGTx Reacquires Bota-Vec from J&J; Plans 2027 Launch
AI Summary
MeiraGTx Holdings plc announced it has reacquired all interests in botaretigene sparoparvovec (bota-vec) from Johnson & Johnson. Bota-vec is a genetic medicine for the treatment of X-linked retinitis pigmentosa (XLRP), a condition with no alternative treatment. MeiraGTx intends to immediately pursue global regulatory filings in the U.S., EU, and Japan, aiming for a potential launch in 2027, supported by positive Phase 3 LUMEOS study data.
Key Highlights
- MeiraGTx reacquired all interests in bota-vec for X-linked retinitis pigmentosa (XLRP) treatment from Johnson & Johnson.
- Company plans to immediately pursue global regulatory filings (BLA, MAA) in the U.S., EU, and Japan.
- MeiraGTx aims for a potential launch of bota-vec in 2027.
- Phase 3 LUMEOS study data showed meaningful improvements in vision for XLRP patients.
- MeiraGTx has completed PPQ with CMC datasets for regulatory filing.